Beam Therapeutics Doses First Patient in BEAM-302 Pivotal Cohort

Company: Beam Therapeutics · Event Type: Pivotal Trial Milestone · Modality: In Vivo Liver-Directed Base Editing (LNP-Delivered) · Asset: BEAM-302 · Target: SERPINA1 (PiZ Allele) · Disease Area: Alpha-1 Antitrypsin Deficiency Summary Beam Therapeutics dosed the first participant in the global pivotal cohort of BEAM-302,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs
Beeline Therapeutics – $300M Launch
Repligen Buys BioLife for $1.5 Billion
Nurix + Roche; Global BTK Degrader Collaboration